-Reuters
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition
UniQure N.V. (NASDAQ:QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common…